213 related articles for article (PubMed ID: 16901281)
1. Identification of T-cell epitopes associated with immunity within the surface protein of duck hepatitis B virus.
Welschinger R; Cossart Y; Pouliopoulos J; Dixon R; Vickery K
J Viral Hepat; 2006 Aug; 13(8):515-22. PubMed ID: 16901281
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
Miller DS; Halpern M; Kotlarski I; Jilbert AR
Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
[TBL] [Abstract][Full Text] [Related]
3. The early host innate immune response to duck hepatitis B virus infection.
Tohidi-Esfahani R; Vickery K; Cossart Y
J Gen Virol; 2010 Feb; 91(Pt 2):509-20. PubMed ID: 19846670
[TBL] [Abstract][Full Text] [Related]
4. Identification of major antigenic domains of duck hepatitis B virus pre-S protein by peptide scanning.
Chassot S; Lambert V; Kay A; Godinot C; Trepo C; Cova L
Virology; 1994 Apr; 200(1):72-8. PubMed ID: 7510440
[TBL] [Abstract][Full Text] [Related]
5. Cellular immune response of ducks to duck hepatitis B virus infection.
Vickery K; Cossart Y; Dixon R
J Med Virol; 1999 May; 58(1):19-25. PubMed ID: 10223541
[TBL] [Abstract][Full Text] [Related]
6. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
7. Elimination of immune tolerance to hepatitis virus in an animal model.
Wen YM; Zhang W; Xu YY; Luo YF; Li PY
Chin Med J (Engl); 1992 Mar; 105(3):199-203. PubMed ID: 1395838
[TBL] [Abstract][Full Text] [Related]
8. The effect of surgical immunomodulation on liver inflammation and clearance of DHBV infection.
Vickery K; Tohidi-Esfahani R; Pouliopoulos J; Welschinger R; Dixon R; Deva A; Cossart Y
J Med Virol; 2006 Dec; 78(12):1572-8. PubMed ID: 17063509
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the kinetics of the specific cellular immune response to duck hepatitis B virus in infected and immune ducks.
Vickery K; Cossart Y; Dixon R
Vet Microbiol; 1999 Aug; 68(1-2):157-69. PubMed ID: 10501173
[TBL] [Abstract][Full Text] [Related]
10. Alternative methods for validation of cell culture infection with duck hepatitis B virus.
Sauerbrei A; Schacke M; Schultz U; Egerer R; Merkle I; Glebe D; Gerlich W; Wutzler P
J Virol Methods; 2005 Nov; 129(2):178-85. PubMed ID: 16002155
[TBL] [Abstract][Full Text] [Related]
11. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner.
Miller DS; Kotlarski I; Jilbert AR
Virology; 2006 Jul; 351(1):159-69. PubMed ID: 16624364
[TBL] [Abstract][Full Text] [Related]
13. Single B or T-cell epitope-based DNA vaccine using modified vector induces specific immune response against hepadnavirus.
Xu HB; Xu W; Chu YW; Wang Y; Xiong S
Immunol Lett; 2005 Jul; 99(2):186-92. PubMed ID: 16009269
[TBL] [Abstract][Full Text] [Related]
14. Duck hepatitis B virus: an invaluable model system for HBV infection.
Schultz U; Grgacic E; Nassal M
Adv Virus Res; 2004; 63():1-70. PubMed ID: 15530560
[No Abstract] [Full Text] [Related]
15. In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins.
Khawaja G; Buronfosse T; Jamard C; Abdul F; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans CF; Hartmann D; Cova L
Virology; 2012 Nov; 433(1):192-202. PubMed ID: 22921316
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of specific immune responses to duck hepatitis B virus in infected, immune, and uninfected ducks].
Tang N; Huang A; Guo S; Qi Z; Zhang D
Zhonghua Gan Zang Bing Za Zhi; 2001 Jun; 9(3):166-8. PubMed ID: 11412394
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks.
Jilbert AR; Miller DS; Scougall CA; Turnbull H; Burrell CJ
Virology; 1996 Dec; 226(2):338-45. PubMed ID: 8955053
[TBL] [Abstract][Full Text] [Related]
18. Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation.
Khawaja G; Buronfosse T; Jamard C; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans C; Hartmann D; Cova L
Virology; 2012 Mar; 425(1):61-9. PubMed ID: 22284894
[TBL] [Abstract][Full Text] [Related]
19. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes.
Saade F; Buronfosse T; Pradat P; Abdul F; Cova L
Vaccine; 2008 Sep; 26(40):5159-64. PubMed ID: 18554756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
